Evidence map›Paper›PMID 40551353›Full record

ArticleJournal of biophotonics2025

Use of Mitochondrial Delayed Luminescence Measurements From Brain Tissue to Optimize Photobiomodulation Prarameters in Alzheimer's Disease Mice.

Hong Bae Kim, Chang Kyu Sung

Abstract read
In one paragraph

Article in Journal of biophotonics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hong Bae KimBioEngineering Institute of Chang Healthcare, Chang Healthcare, Co. Ltd, Seoul, Republic of Korea.ORCID 0000-0002-1661-6585
Chang Kyu SungBioEngineering Institute of Chang Healthcare, Chang Healthcare, Co. Ltd, Seoul, Republic of Korea.

Funding

Chang HealthcareSeoul National University
6 · The paper itself

Abstract

The therapeutic potential of photobiomodulation (PBM) for Alzheimer's disease (AD) was evaluated by examining β-amyloid accumulation, microglial activation, and memory function. Mitochondrial delayed luminescence (m-DL), an indirect mitochondrial marker, was measured by irradiating 2 J/cm

Indexed as

Alzheimer DiseaseBrainLow-Level Light TherapyLuminescent MeasurementsMitochondriaAmyloid beta-PeptidesAnimalsMiceMice, TransgenicAmyloid beta-PeptidesAlzheimer's diseaseamyloid clearancemitochondrial delayed luminescencephotobiomodulationpulsed wave

Identifiers

PMID40551353
PMCPMC12507487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.